IP Infusion now has 600 customers, 40 ODM platforms, over 100 solution partners, and more than 1.5M switch ports sold worldwide
SANTA CLARA, Calif., Aug. 31, 2023 – IP Infusion, a leading manufacturer of carrier-grade networking software, today announced an 87% USD year-over-year revenue growth in the first half of 2023, buoyed by vigorous global sales and licensing. In the first six months of 2023, IP Infusion gained 51 new customers and added 14 new channel partners. The OcNOS Aggregation Router, Data Center, and Cell Site Router use cases lead sales, with switch and router port shipments for all OcNOS licenses sold at more than 1.5 million ports.
2023 announced customer wins include: Amplex Internet, Broadstar, DojoNetworks, MetaLINK Technologies, Multinet, Netplus, Pine Networks, Telcom，以及 Vyve Broadband. These new customer wins, as well as the 163 repeat orders from existing customers in 1H23, cement IP Infusion's role as an appealing disaggregated alternative to legacy vendors including Cisco, Juniper, and Arista. Customers cite IP Infusion's attributes including its "super technology" and "flexibility at a lower price point than traditional solutions." They also noted that IP Infusion's solution strategically positions them for further expansion. IP Infusion also announced this year that the company collaborated with NTT Corporation (NTT) for the development of Beluganos, a new network operating system to realize NTT's IOWN concept, and is providing sales and support for its global markets.
"This continued growth over the first six months of 2023, succeeding record gains in 2022, further validates IP Infusion's position as the open network software and solution leader for service providers and data centers," said Atsushi Ogata, President and CEO of IP Infusion. "Our field-tested platform continues to build significant market share in this space through extensive use cases and successful deployments that spark innovation and lower total cost of ownership."
In addition to continued positive customer and sales momentum, IP Infusion also earned prestigious industry recognition in 1H2023. GigaOm, leading independent global provider of technology industry insights, designated IP Infusion a Leader, Outperformer and Platform player for all of its annual 2023 Network Operating System (NOS) Radar Reports. This is the third consecutive year IP Infusion's OcNOS® platform has been identified as the most complete of the more than 20 NOS vendors GigaOm analysts evaluated, outperforming incumbent providers including Cisco and Juniper.
关于 IP Infusion
IP Infusion manufactures open network software and solutions for carriers, service providers and data centers. With hundreds of customers and thousands of deployments, IP Infusion is a market leader in Network Operating Systems. Our flagship software platform OcNOS® allows network operators to disaggregate their networks, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier-grade robustness.
IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.
IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.
-end-
Media Contact:
Katherine Verducci
1903 PR
kverducci@1903pr.com
408.429.5779
关于 IP Infusion
IP Infusion 是开放网络软件的领先供应商，提供面向服务提供商、数据中心和 AI Fabric 网络的运营商级网络操作系统 OcNOS。凭借自 1999 年以来的网络技术积累和全球 600+ 家运营商的部署，IP Infusion 在 Edgecore Networks、UfiSpace 和 Celestica 等合作伙伴经过验证的开放硬件上，实现开放、多厂商、高性价比且灵活的网络基础设施。IP Infusion 是 ACCESS CO., LTD.（东京证券交易所：4813）的全资子公司。
媒体联系
For press inquiries, analyst briefings, or media materials, please 联系我们团队 or email pr@ipinfusion.com.
前瞻性陈述
本新闻稿可能包含有关 IP Infusion 产品、技术和计划的前瞻性陈述。前瞻性陈述基于发布之日可获得的信息，涉及风险和不确定性，实际结果可能存在差异。产品计划、功能、发布时间和供应情况可能随时变更，恕不另行通知，且不构成任何承诺、保证或法律义务。IP Infusion 不承担更新任何前瞻性陈述的义务。